In this regard, MDM2 is considered as an onco-protein by accelerating tumor growth and promoting cancer progression in a p53-dependent manner8–10; hence, small molecule inhibitors targeting MDM2-p53 interaction, such as Nutlin-3a, have been developed for the treatment of various types of cancer and are under clinical trial presently11–13. This evidence concerns the gene MDM2 and neoplasm.